GPT and metabolic dysfunction-associated steatotic liver disease: Although fibrates have demonstrated worsening of liver and kidney function test results, pemafibrate significantly reduces the levels of alanine aminotransferase (ALT) and gamma‐glutamyl transpeptidase (GGT) without increasing serum creatinine or decreasing estimated glomerular filtration rate (eGFR) in patients with NAFLD.14, 15, 16, 17, 18, 19